In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

External validation and comparison of the CardShock and IABPII shock risk scores in real-life cardiogenic shock patients

Session Moderated Poster Session - Acute heart failure

Speaker Javier Segovia Cubero

Congress : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure - Epidemiology, Prognosis, Outcome
  • Session type : Moderated Posters
  • FP Number : 44

Authors : M Rivas Lasarte (Barcelona,ES), J Sans-Rosello (Barcelona,ES), E Collado Lledo (Barcelona,ES), V Gonzalez Fernandez (Barcelona,ES), J Fernandez Martinez (Barcelona,ES), F Noriega Sanz (Madrid,ES), F Hernandez Perez (Madrid,ES), J Segovia (Madrid,ES), A Viana (Madrid,ES), RM Lidon (Barcelona,ES), A Ariza (Barcelona,ES), A Sionis (Barcelona,ES)

M Rivas Lasarte1 , J Sans-Rosello1 , E Collado Lledo2 , V Gonzalez Fernandez3 , J Fernandez Martinez1 , F Noriega Sanz4 , F Hernandez Perez5 , J Segovia5 , A Viana4 , RM Lidon3 , A Ariza2 , A Sionis1 , 1Hospital de la Santa Creu i Sant Pau, Cardiology Department - Barcelona - Spain , 2University Hospital of Bellvitge, Cardiology - Barcelona - Spain , 3University Hospital Vall d'Hebron, Cardiology - Barcelona - Spain , 4Hospital Clínico San Carlos, Cardiology - Madrid - Spain , 5University Hospital Puerta de Hierro Majadahonda, Cardiology - Madrid - Spain ,


Background: The recently published CardShock and the IABPII-Shock scores have shown a good performance in predicting short-term mortality. To date, they have not been compared in a large cohort of real-life patients.

Methods: This is a multicenter retrospective cohort study of CS patients. 

Results: The 696 patients with complete data were analyzed. Acute Coronary Syndrome (ACS) was the main cause of shock in 62% of patients. The main characteristics of patients are summarized in the table. The Cardshock risk score and the IABPII risk score were good in-hospital mortality predictors with similar Areas Under the ROC Curve in ACS patients (AUC: 0.742 vs 0.752, p=0.551). The discrimination performance dropped when the scores were applied to non-ACS patients (0.648 vs 0.619, respectively p=0.310). Calibration was acceptable for both scores (non-significant Hosmer-Lemeshow test).

Conclusions: The Cardshock and the IABPII shock risk scores were good predictors of in-hospital mortality. The lower ability of both scores to predict the short-term prognosis in non-ACS patients may be related to their marked heterogeneity.


434 patients



262 patients


Age (years), mean (SD) 68 (13) 61 (16) <0.0001
Hypertension 281 (65%) 133 (51%) <0.001
Diabetes 183 (42%) 100 (38%) 0.298
Smokers 159 (37%) 71 (27%) 0.028
Renal insufficiency 61 (14%) 61 (23%) 0.002
Previous myocardial infarction 77 (18%) 63 (24%) 0.044
Previous heart failure 46 (10%) 151 (58%) <0.001
Cardiac arrest 119 (27%) 25 (13%) <0.001
CardShock risk score, mean (SD) 5 (2) 4 (2) <0.0001
IABPIIshock risk score, mean (SD) 2.8(1.8) 2.0 (1.6) <0.0001
Dobutamine 392 (90%) 237 (90%) 0.953
Invasive mechanical ventilation 275 (63%) 156 (60%) 0.314
Renal replacement therapy 80 (18%) 53 (20%) 0.543
IABP 245 (56%) 82 (31%) <0.001
LVAD or BiVAD (Levitronix) 14 (3%) 28 (11%) <0.001
In-hospital mortality 198 (45%) 112 (43%) 0.460

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are